200 related articles for article (PubMed ID: 37280473)
1. IL-6-induced response of human osteoblasts from patients with rheumatoid arthritis after inhibition of the signaling pathway.
Sellin ML; Klinder A; Bergschmidt P; Bader R; Jonitz-Heincke A
Clin Exp Med; 2023 Nov; 23(7):3479-3499. PubMed ID: 37280473
[TBL] [Abstract][Full Text] [Related]
2. Effects of the Interleukin-6 Receptor Blocker Sarilumab on Metabolic Activity and Differentiation Capacity of Primary Human Osteoblasts.
Klinder A; Waletzko-Hellwig J; Sellin ML; Seyfarth-Sehlke A; Wolfien M; Prehn F; Bader R; Jonitz-Heincke A
Pharmaceutics; 2022 Jun; 14(7):. PubMed ID: 35890286
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation.
Kotake S; Sato K; Kim KJ; Takahashi N; Udagawa N; Nakamura I; Yamaguchi A; Kishimoto T; Suda T; Kashiwazaki S
J Bone Miner Res; 1996 Jan; 11(1):88-95. PubMed ID: 8770701
[TBL] [Abstract][Full Text] [Related]
4. IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17.
Hashizume M; Hayakawa N; Mihara M
Rheumatology (Oxford); 2008 Nov; 47(11):1635-40. PubMed ID: 18786965
[TBL] [Abstract][Full Text] [Related]
5. IL-6/sIL-6R trans-signalling, but not TNF-alpha induced angiogenesis in a HUVEC and synovial cell co-culture system.
Hashizume M; Hayakawa N; Suzuki M; Mihara M
Rheumatol Int; 2009 Oct; 29(12):1449-54. PubMed ID: 19277666
[TBL] [Abstract][Full Text] [Related]
6. LIPUS inhibited the expression of inflammatory factors and promoted the osteogenic differentiation capacity of hPDLCs by inhibiting the NF-κB signaling pathway.
Liu S; Zhou M; Li J; Hu B; Jiang D; Huang H; Song J
J Periodontal Res; 2020 Jan; 55(1):125-140. PubMed ID: 31541455
[TBL] [Abstract][Full Text] [Related]
7. Increased sensitivity of rheumatoid synoviocytes to Schnurri-3 expression in TNF-α and IL-17A induced osteoblastic differentiation.
Lavocat F; Osta B; Miossec P
Bone; 2016 Jun; 87():89-96. PubMed ID: 27072520
[TBL] [Abstract][Full Text] [Related]
8. Inflammatory Response of Human Peripheral Blood Mononuclear Cells and Osteoblasts Incubated With Metallic and Ceramic Submicron Particles.
Klinder A; Seyfarth A; Hansmann D; Bader R; Jonitz-Heincke A
Front Immunol; 2018; 9():831. PubMed ID: 29922277
[TBL] [Abstract][Full Text] [Related]
9. Disease-Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid Arthritis.
Lee EB; Daskalakis N; Xu C; Paccaly A; Miller B; Fleischmann R; Bodrug I; Kivitz A
Clin Pharmacokinet; 2017 Jun; 56(6):607-615. PubMed ID: 27722854
[TBL] [Abstract][Full Text] [Related]
10. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis.
Raimondo MG; Biggioggero M; Crotti C; Becciolini A; Favalli EG
Drug Des Devel Ther; 2017; 11():1593-1603. PubMed ID: 28579757
[TBL] [Abstract][Full Text] [Related]
11. Gp130 activation by soluble interleukin-6 receptor/interleukin-6 enhances osteoblastic differentiation of human bone marrow-derived mesenchymal stem cells.
Erices A; Conget P; Rojas C; Minguell JJ
Exp Cell Res; 2002 Oct; 280(1):24-32. PubMed ID: 12372336
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-6 upregulates expression of ADAMTS-4 in fibroblast-like synoviocytes from patients with rheumatoid arthritis.
Mimata Y; Kamataki A; Oikawa S; Murakami K; Uzuki M; Shimamura T; Sawai T
Int J Rheum Dis; 2012 Feb; 15(1):36-44. PubMed ID: 22324945
[TBL] [Abstract][Full Text] [Related]
13. IL-6 and sIL-6R induces STAT3-dependent differentiation of human VSMCs into osteoblast-like cells through JMJD2B-mediated histone demethylation of RUNX2.
Kurozumi A; Nakano K; Yamagata K; Okada Y; Nakayamada S; Tanaka Y
Bone; 2019 Jul; 124():53-61. PubMed ID: 30981888
[TBL] [Abstract][Full Text] [Related]
14. Shedding of the interleukin-6 (IL-6) receptor (gp80) determines the ability of IL-6 to induce gp130 phosphorylation in human osteoblasts.
Vermes C; Jacobs JJ; Zhang J; Firneisz G; Roebuck KA; Glant TT
J Biol Chem; 2002 May; 277(19):16879-87. PubMed ID: 11884403
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-6 and its soluble receptor regulate the expression of insulin-like growth factor binding protein-5 in osteoblast cultures.
Franchimont N; Durant D; Canalis E
Endocrinology; 1997 Aug; 138(8):3380-6. PubMed ID: 9231791
[TBL] [Abstract][Full Text] [Related]
16. Oestrogens prevent the increase of human serum soluble interleukin-6 receptor induced by ovariectomy in vivo and decrease its release in human osteoblastic cells in vitro.
Girasole G; Giuliani N; Modena AB; Passeri G; Pedrazzoni M
Clin Endocrinol (Oxf); 1999 Dec; 51(6):801-7. PubMed ID: 10619987
[TBL] [Abstract][Full Text] [Related]
17. Regulatory effect of calcineurin inhibitor, tacrolimus, on IL-6/sIL-6R-mediated RANKL expression through JAK2-STAT3-SOCS3 signaling pathway in fibroblast-like synoviocytes.
Choe JY; Park KY; Park SH; Lee SI; Kim SK
Arthritis Res Ther; 2013 Feb; 15(1):R26. PubMed ID: 23406906
[TBL] [Abstract][Full Text] [Related]
18. Combination of interleukin-6 and soluble interleukin-6 receptors induces differentiation and activation of JAK-STAT and MAP kinase pathways in MG-63 human osteoblastic cells.
Nishimura R; Moriyama K; Yasukawa K; Mundy GR; Yoneda T
J Bone Miner Res; 1998 May; 13(5):777-85. PubMed ID: 9610741
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-35 stimulates tumor necrosis factor-α activated osteoblasts differentiation through Wnt/β-catenin signaling pathway in rheumatoid arthritis.
Li Y; Yuan L; Jiang S; Liu S; Xia L; Shen H; Lu J
Int Immunopharmacol; 2019 Oct; 75():105810. PubMed ID: 31404890
[TBL] [Abstract][Full Text] [Related]
20. IL-6 amplifies TLR mediated cytokine and chemokine production: implications for the pathogenesis of rheumatic inflammatory diseases.
Caiello I; Minnone G; Holzinger D; Vogl T; Prencipe G; Manzo A; De Benedetti F; Strippoli R
PLoS One; 2014; 9(10):e107886. PubMed ID: 25271853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
